Yingke PE, an investment firm with nearly 50 billion yuan ($7.8 billion) in total assets, has announced the final close for its third US dollar-denominated fund, which will invest in biomedicine startups.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
